Prime Medicine (PRME) Cash & Equivalents (2021 - 2026)

Prime Medicine (PRME) has 6 years of Cash & Equivalents data on file, last reported at $64.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 30.23% year-over-year to $64.1 million; the trailing twelve-month figure through Mar 2026 stood at $64.1 million (down 30.23% YoY), and the FY2025 full-year result was $63.0 million, down 65.46% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $64.1 million, up from $63.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $187.6 million in Q4 2022 and bottomed at $41.6 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $91.9 million (2025), against an average of $95.7 million.
• The widest annual swing landed in 2023, when Cash & Equivalents slumped 77.84%; it then jumped 338.92% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $187.6 million in 2022, then plunged by 77.84% to $41.6 million in 2023, then soared by 338.92% to $182.5 million in 2024, then plunged by 65.46% to $63.0 million in 2025, then advanced by 1.7% to $64.1 million in 2026.
• The last three Cash & Equivalents figures came in at $64.1 million (Q1 2026), $63.0 million (Q4 2025), and $71.4 million (Q3 2025), per Business Quant data.

Peer Comparison